Reimagining dementia screening: A stakeholder-informed perspective on artificial intelligence, digital biomarkers, and real-world implementation
{{output}}
The approval of disease-modifying treatments for Alzheimer's disease demands a rethinking of cognitive screening. Drawing on over 180 stakeholder interviews from the NSF National I-Corps program, this perspective highlights barriers in current workflows, from... ...
